Protagonist Therapeutics, Inc.
PTGX
Pozycja w akcjach
#2299
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Cena akcji
$134.37
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$8.70B
Zmiana (1 dzień)
4.37%
Zmiana (1 rok)
75.15%
Kraj
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategoria
Healthcare
EPS dla Protagonist Therapeutics, Inc. (PTGX)
EPS na dzień June 2026 TTM: $1.22
Według najnowszych raportów finansowych i ceny akcji firmy Protagonist Therapeutics, Inc., obecny EPS (TTM) wynosi $1.22. Na koniec roku 2023 firma miała EPS w wysokości $-1.39, spadek w porównaniu do do EPS z roku 2022, który wynosił $-2.52.
Historia EPS dla Protagonist Therapeutics, Inc. od 2014 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $1.22 | -72.71% |
| 2024 | $4.47 | -421.58% |
| 2023 | $-1.39 | -44.84% |
| 2022 | $-2.52 | -4.91% |
| 2021 | $-2.65 | 38.02% |
| 2020 | $-1.92 | -35.57% |
| 2019 | $-2.98 | 71.26% |
| 2018 | $-1.74 | -16.75% |
| 2017 | $-2.09 | -63.46% |
| 2016 | $-5.72 | 126.98% |
| 2015 | $-2.52 | 34.04% |
| 2014 | $-1.88 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | 1,319.67% |
US
|
|
| $-7.98 | -754.10% |
US
|
|
| $-5.29 | -533.61% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 2,173.77% |
NL
|
